An observational study in Skin Cancer and Skin Diseases, sponsored by Barco NV. Active, not recruiting at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-05.
Sponsored by Barco NV · Observational
This is a multicenter prospective observational clinical investigation with a medical device. The purpose of this study is to develop and validate of a new type of digital dermatoscope with automatic decision support algorithms. By means of this study a better insight can be gained of the current performance and workflow in clinical dermatoscopy. This knowledge will be used to further improve the developed technology.
Patients will be considered for enrollment in the study when they have a lesion that is accessible to the Barco Digital Dermatoscope, are able to give informed consent and are over 18 years old.
Exclusion Criteria:
Images of skin lesion taken with the Barco dermatoscope by site team member
Images of skin lesion taken with a standard dermatoscope device (as part of standard care)
Development of anonymized database with over 3000 (potential) skin cancer cases for use in AI
Database of multispectral images of potential skin cancer lesions acquired with the Barco device together with clinical information (e.g. age, gender, history of skin cancer, histopathology diagnosis) and matched standard images using medical photography
Time frame: 3.5 years
Comparison of new device to standard dermoscopy
Compare clinical performance and workflow efficiency of the Barco device to current standard of care (standard dermoscopy)
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.